ClinicalTrials.govpublic full text
Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
pulmonary infections, pseudomonas aeruginosa in cystic fibrosis, tobramycin inhalation powder, cystic fibrosis, lung disease, anti-bacterial agents, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1046410
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.